Drug Trial Radar · NCT07579910
Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
14
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Aug 2033
Study completion Aug 2033
Sponsor
- Lead sponsor
- Spruce BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition
Conditions
- MPS IIIB
Interventions
Tralesinidase alfa (TA)Drug
TA study drug is a sterile solution for ICV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Bayley Scales of Infant and Toddler Development, Third Edition, Cognition Domain (BSID-III-C) Raw ScoreTime frame: Baseline to Week 260 (approximately 5 years)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.